In a remarkable advancement that addresses the escalating global challenge of measles outbreaks, the Vanderbilt Center for Antibody Therapeutics has entered into a strategic option agreement with Saravir Biopharma Inc. This collaboration is aimed at developing cutting-edge human monoclonal antibodies designed to treat and prevent measles infection. These antibodies were originally isolated through pioneering research conducted in the laboratory of Dr. James Crowe Jr., a leading figure in infectious disease immunology. As vaccination rates have declined and measles cases surge worldwide, this breakthrough represents a critical intervention, especially for populations vulnerable to severe complications or mortality from measles.
The resurgence of measles after years of near elimination underscores an urgent need for novel therapeutic modalities. Measles, caused by a highly contagious respiratory virus, poses significant risk to individuals who cannot mount an adequate immune response, including pregnant women and the immunocompromised. The traditional live-virus measles vaccine, while highly effective in healthy individuals, is contraindicated for these at-risk groups. Monoclonal antibody therapy offers a promising alternative because it can provide passive immunity by directly neutralizing the virus, thereby offering immediate protection without relying on the host’s immune activation.
Preclinical investigations into the efficacy of these monoclonal antibodies have demonstrated potent neutralization of measles virus particles in various animal models. Although these data are pending publication, Dr. Ronald Moss, President and CEO of Saravir Biopharma, describes the results as very promising. The antibodies specifically target viral fusion proteins expressed on measles-infected cells and free virus particles, blocking the fusion process essential for viral entry and spread. By impeding this critical mechanism, the antibodies effectively prevent infection at the cellular level, which is a novel approach to measles management.
Saravir Biopharma, headquartered in Encinitas, California, was co-founded by Dr. Moss, an experienced physician-scientist with a track record of leading antiviral and vaccine development from fundamental research to advanced clinical trials. Saravir’s mission is to develop the first monoclonal antibody-based therapeutic against measles, addressing an urgent unmet clinical need. The collaboration with Vanderbilt leverages access to human monoclonal antibodies derived from natural human immune responses, providing a strong foundation for therapeutic success.
Dr. James Crowe Jr., director of the Vanderbilt Center for Antibody Therapeutics and a University Distinguished Professor of Pediatrics and Chemistry, has been instrumental in advancing monoclonal antibody research targeting a spectrum of viral pathogens. His laboratory’s expertise in isolating and characterizing neutralizing antibodies underpins this initiative. The antibodies developed demonstrate specificity toward measles virus fusion proteins, a critical viral envelope component responsible for initiating host cell entry. Such targeted therapy could revolutionize prophylactic and treatment strategies for measles.
Historically, the United States achieved near elimination of measles due to high vaccination coverage, but recent trends reveal an alarming increase in cases. The Centers for Disease Control and Prevention (CDC) reported 2,285 confirmed measles cases in 2025, with an additional 1,575 cases reported in the first quarter of 2026 alone. This resurgence is attributed largely to declining vaccine coverage and increasing vaccine hesitancy, which undermines herd immunity and facilitates viral transmission.
Monoclonal antibody therapy offers several advantages over existing vaccines in specific patient populations. Besides immediate action, antibodies can be administered to individuals contraindicated for vaccination, offering protective benefits without necessitating an active immune response. This approach is especially vital for pregnant women and immunocompromised patients, who are disproportionately susceptible to severe complications. By neutralizing the virus extracellularly and at the infected cell surface, these antibodies halt disease progression and prevent transmission.
The next phase in the development pipeline involves initiating human clinical trials to establish safety, dosage, and efficacy profiles. While traditional pharma development timelines are extensive, the accelerating spread of measles may enable regulatory agencies to fast-track these processes, expediting access to life-saving therapies. Saravir Biopharma, in partnership with Vanderbilt, is poised to navigate these clinical stages efficiently, aiming to deliver an effective monoclonal antibody therapy within a shortened timeframe.
Dr. Moss emphasized the determination of his team to advance these antibodies despite the inherent challenges. The long-predicted resurgence of measles outbreaks necessitates rapid and innovative countermeasures. With extensive expertise in antiviral drug development, Saravir’s leadership is well-suited to translate Vanderbilt’s scientific discoveries into clinically viable therapeutics aimed at curbing measles transmission and mitigating disease severity.
In summary, this collaboration represents a transformative approach to infectious disease therapeutics by combining cutting-edge antibody engineering with an acute public health need. The monoclonal antibodies developed at Vanderbilt, now being advanced by Saravir Biopharma, are poised to become a critical adjunct to vaccination programs, providing protection for vulnerable groups and potentially altering the landscape of measles prevention and treatment. As measles continues to threaten global health despite available vaccines, these innovative therapies could play a decisive role in future outbreak responses.
The scientific community and public health officials alike recognize the importance of this advancement as a potential game-changer in infectious disease control. By harnessing the precision of monoclonal antibodies, this therapeutic strategy offers hope for reducing the incidence and severity of measles worldwide. Continued research, rigorous clinical testing, and regulatory scrutiny will be essential to realize the full potential of this promising new treatment.
As research progresses, public awareness and support for antibody therapies will be crucial. These therapies may set a precedent for similar interventions for other viral infections, especially where traditional vaccination approaches face limitations due to immune system constraints or safety concerns. The development of anti-measles monoclonal antibodies thus represents a significant milestone in the broader field of antiviral therapeutics and immunology.
Subject of Research: Development of human monoclonal antibody therapy for measles treatment and prevention
Article Title: Vanderbilt Center for Antibody Therapeutics and Saravir Biopharma Collaborate to Develop Human Monoclonal Antibodies Targeting Measles Virus
News Publication Date: Not specified
Web References:
– Vanderbilt Center for Antibody Therapeutics: https://www.vumc.org/vcat/home
– Saravir Biopharma: http://www.saravir.com
– James Crowe Jr., MD: https://www.vumc.org/crowe-lab/person/james-crowe-md
Image Credits: Illustration by Elad Binshtein, PhD, senior scientist – cryo-EM in the Crowe lab, Vanderbilt Health © Elad Binshtein/Vanderbilt Health
Keywords: Measles, Monoclonal antibody therapy, Viral fusion proteins, Infectious diseases, Antiviral therapeutics, Immune-compromised patients, Vaccine alternatives
Tags: antibody neutralization of measles viruschallenges in measles vaccinationhuman monoclonal antibodies for measlesinnovative infectious disease therapeuticsmeasles infection preventionmeasles outbreak responsemeasles treatment for immunocompromisedmonoclonal antibody therapy for viral infectionsnovel anti-measles antibody treatmentpassive immunity against measlesSaravir Biopharma collaborationVanderbilt Center for Antibody Therapeutics
